Modified Pseudomonas exotoxin A

US9388222B2 · kind B2 · utility

Assignees

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US
• Hoffmann-La Roche Inc. · US

Inventors

• Ira H. Pastan · Potomac, US
• Ronit Mazor · Rockville, US
• Masanori Onda · Germantown, US
• Byungkook Lee · Potomac, US
• Gerhard Niederfellner · Oberhausen, DE
• Sabine Imhof-Jung · Planegg, DE
• Ulrich Brinkmann · Weilheim, DE
• Guy Georges · Habach, DE

Key dates

• Filing date: Oct 3, 2014
• Grant date: Jul 12, 2016
• Expiry date: Oct 3, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/55
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more B-cell and/or T-cell epitopes. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.